Exaggerated Vascular and Renal Pathology in Endothelin-B Receptor-deficient Rats with Deoxycorticosterone Acetate-salt Hypertension
Overview
Authors
Affiliations
Background: Endothelin (ET)-1 plays an important role in the pathogenesis of deoxycorticosterone acetate (DOCA)-salt-induced hypertension. We evaluated the pathological role of ET(B) receptors in DOCA-salt-induced hypertension, cardiovascular hypertrophy, and renal damage by using the spotting-lethal (sl) rat, which carries a naturally occurring deletion in the ET(B) receptor gene.
Methods And Results: Homozygous (sl/sl) rats exhibit abnormal development of neural crest-derived epidermal melanocytes and the enteric nervous system, and they do not live beyond 1 month because of intestinal aganglionosis and intestinal obstruction. The dopamine ss-hydroxylase (DssH) promoter was used to direct ET(B) transgene expression in sl/sl rats to support normal enteric nervous system development. DssH-ET(B) sl/sl rats live into adulthood and are healthy, expressing ET(B) receptors in adrenal glands and other adrenergic neurons. When homozygous (sl/sl) and wild-type (+/+) rats, all of which were transgenic, were treated with DOCA-salt, homozygous rats exhibited earlier and higher increases in systolic blood pressure than did wild-type rats. Chronic treatment with ABT-627, an ET(A) receptor antagonist, completely suppressed DOCA-salt-induced hypertension in both groups. Renal dysfunction and histological damage were more severe in homozygous than in wild-type rats. Marked vascular hypertrophy was observed in homozygous rats than in wild-type rats. Renal and vascular injuries were significantly improved by ABT-627. In DOCA-salt-treated homozygous rats, there were notable increases in renal, urinary, and aortic ET-1, all of which were normalized by ABT-627.
Conclusions: ET(B)-mediated actions are protective in the pathogenesis of DOCA-salt-induced hypertension. Enhanced ET-1 production and ET(A)-mediated actions are responsible for the increased susceptibility to DOCA-salt hypertension and tissue injuries in ET(B) receptor-deficient rats.
Sharma P, Kaushik P, Jain S, Sharma B, Awasthi R, Kulkarni G Clin Psychopharmacol Neurosci. 2021; 19(3):470-489.
PMID: 34294616 PMC: 8316668. DOI: 10.9758/cpn.2021.19.3.470.
Lu R, Zheng X Thromb Haemost. 2021; 122(3):344-352.
PMID: 33984867 PMC: 9514555. DOI: 10.1055/a-1508-8347.
Becker B, Johnston J, Young C, Torres Rodriguez A, Jin C, Pollock D Auton Neurosci. 2021; 232:102796.
PMID: 33798837 PMC: 8040376. DOI: 10.1016/j.autneu.2021.102796.
Kidney dysfunction in patients with pulmonary arterial hypertension.
Nickel N, OLeary J, Brittain E, Fessel J, Zamanian R, West J Pulm Circ. 2017; 7(1):38-54.
PMID: 28680564 PMC: 5448543. DOI: 10.1086/690018.
Davenport A, Hyndman K, Dhaun N, Southan C, Kohan D, Pollock J Pharmacol Rev. 2016; 68(2):357-418.
PMID: 26956245 PMC: 4815360. DOI: 10.1124/pr.115.011833.